Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Fresh from the Pipeline
  • Published:

Telbivudine

Abstract

Telbivudine (Tyzeka; Idenix/Novartis), a nucleoside analogue that inhibits the hepatitis B virus polymerase, was approved by the US FDA in October 2006 for the treatment of adults with chronic hepatitis B.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Telbivudine.

References

  1. Lee, W. M. Hepatitis B virus infection N. Engl. J. Med. 337, 1733–1745 (1997).

    Article  CAS  Google Scholar 

  2. Jacobson, I. M. Therapeutic options for chronic hepatitis B: considerations and controversies. Am. J. Gastroenterol. 101 (Suppl. 1), 13–17 (2005).

    Google Scholar 

  3. Dienstag, J. L. Looking to the future: new agents for chronic hepatitis B. Am. J. Gastroenterol. 101 (Suppl. 1), 19–25 (2005).

    Google Scholar 

  4. Lai, C. L. et al. Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B. Clin. Infect. Dis. 36, 687–696 (2003).

    Article  CAS  Google Scholar 

  5. Bryant, M. L. et al. Antiviral L-nucleosides specific for hepatitis B virus infection. Antimicrob. Agents Chemother. 45, 229–235 (2001).

    Article  CAS  Google Scholar 

  6. Hernandez-Santiago B. et al. Pharmacology of β-L-thymidine and β-L-2′-deoxycytidine in HepG2 cells and primary human hepatocytes: relevance to chemotherapeutic efficacy against hepatitis B virus. Antimicrob. Agents Chemother. 46, 1728–1733 (2002).

    Article  CAS  Google Scholar 

  7. Food and Drug Administration. FDA labelling information [online], (2006).

  8. Lai, C. L. et al. Telbivudine (LdT) vs. lamivudine for chronic hepatitis B: first-year results from the international Phase III GLOBE trial. Hepatology 42 (Suppl 1), 748A (2005).

    Google Scholar 

  9. Lai, C. L. et al. Results of a one-year international Phase IIb comparative trial of telbivudine, lamivudine, and the combination, in patients with chronic hepatitis B. Hepatology 38 (Suppl 1), 262A (2003).

    Article  Google Scholar 

  10. Chang, T. T. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N. Engl. J. Med. 354, 1001–1010 (2006).

    Article  CAS  Google Scholar 

  11. Lai, C. L. et al. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N. Engl. J. Med. 354, 1011–1020 (2006).

    Article  CAS  Google Scholar 

  12. Chang, T. T. et al. Entecavir maintained virologic suppression through 3 years of treatment in antiviral-naive HBeAg(+) patients (ETV 022/901). Hepatology 44 (Suppl 1), 229A (2006).

    Google Scholar 

  13. Lai, C. L. et al. Two-year results from the GLOBE trial in patients with hepatitis B: greater clinical and antiviral efficacy for telbivudine (LdT) vs. lamivudine. Hepatology 44 (Suppl 1), 222A (2006).

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Ethics declarations

Competing interests

Jules Dienstag has served on or serves on advisory boards for the following companies: GlaxoSmithKline, Vertex, Bristol-Myers Squibb,Gilead Sciences, Idenix, Achillion, Metabasis, SciClone, Nucleonics, Valeant, Wyeth and AstraZeneca. He has acted or is acting as a consultant for Oxxon Therapeutics, CombinatoRx, Pharmasset and Biogen-Idec. In addition, he has been involved with or is involved with committees for Gilead, Schering-Plough Research Institute and Genzyme. He has received research support from Vertex.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Dienstag, J., Easley, C. & Kirkpatrick, P. Telbivudine. Nat Rev Drug Discov 6, 267–268 (2007). https://doi.org/10.1038/nrd2295

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrd2295

This article is cited by

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing